Newsletter

July 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: July Scorecard Number of Signals 21 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 15% Other stats: Number of signals over $10/share 14 Number […]

0Comments

Regeneron Pharmacueticals and Teva Pharmaceutical Report Positive Topline Phase 3 Clinical Trial Results of Fasinumab

On August 16, Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from a Phase 3 clinical trial of Fasinumbab in patients with chronic pain from osteoarthritis of the knee or hip. After 16 weeks, the study met both co-primary endpoints as well as all key secondary endpoints. Patients treated […]

0Comments

Strongbridge Biopharma Reports Positive Results in Phase 3 SONICS Study of RECORLEV

On August 8, Strongbridge Biopharma plc (SBBP) announced top-line results from its Phase 3 SONICS study evaluating RECORLEVTM(levoketoconazole) for the treatment of endogenous Cushing’s syndrome. The open-label, single-arm SONICS study produced statistically significant results of its pre-specified primary endpoint. At six months, 30% of patients demonstrated a normalization rate of Urinary Free Cortisol. Rocket Tickers […]

0Comments

Reata Pharmaceuticals Reports Positive Phase 2 Results From Two Clinical Trials

On July 23, Reata Pharmaceuticals, Inc. (RETA) announced results from two Phase 2 clinical trials of bardoxolone in patients with chronic kidney disease. The one-year results for the Phase 2 portion of CARDINAL, a study of bardoxolone in patients with chronic kidney disease due to Alport syndrome, found that patients had no drug-related negative side […]

0Comments

Aclaris Therapeautics Reports Positive Phase 2 Clinical Trial Results

On June 28, Aclaris Therapeutics (ACRS) reported positive interim results from its Phase 2 clinical trial of AA-202 Topical. The drug is an investigational topical to treat two of the more severe variants of Alopecia Areata. Patients did not experience any treatment-related serious adverse events, and results for the full patient sample will be reported […]

0Comments

IsoRay Receives FDA 510(k) Clearance for GammaTileTM Therapy

On July 9, IsoRay, Inc. (ISR) and GT Medical Technologies, Inc. announced they received FDA 510(k) regulatory clearance for their brachytherapy technology, known as GammaTileTMTherapy. The therapy incorporates proprietary Cesium-131 seeds within customizable collagen-based carriers to treat recurrent brain tumors. The two companies previously executed a ten-year collaborative development agreement.   Rocket Tickers detected the […]

0Comments

June 2018 Scorecard

The June 2018 scorecard for the signals generated from Rocket Tickers can be downloaded here. For more information regarding how you can trade these signals, see the article Trading Clinical Trials Try Rocket Tickers 30 days for free and cancel anytime! Subscribe here and check out the Training Webinar

0Comments

Zafgen Reports Positive Phase 2 Clinical Trial Results for ZGN-1061

On June 23, Zafgen, Inc. (ZFGN) reported positive results from the company’s Phase 2 clinical trial of ZGN-1061. The trial is designed to prove the drug’s efficacy and safety in patients with type 2 diabetes and to establish a minimally effective dose. Zafgen reported that the patients had no treatment-related serious adverse events.   Rocket Tickers […]

0Comments

Global Blood Therapeutics Reports Positive Phase 3 HOPE Study Results

Global Blood Therapeutics, Inc. (GBT) announced its positive top-line Phase 3 clinical trial data on June 27. The results are from Part A of the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymEmerization) Study to evaluate the use of voxelotor as a treatment for sickle cell disease. On the primary endpoint, patients […]

0Comments

Ironwood Pharmaceuticals Receives FDA Orphan Drug Designation for Olinciguat

Ironwood Pharmaceuticals Inc. (IRWD) announced on June 7 that the FDA granted Orphan Drug Designation to Olinciguat (IW-1701) for patients with sickle cell disease. The FDA grants orphan status to drugs that are intended to treat rare disorders that affect fewer than 200,000 patients in the United States. The designation gives the developer fee waivers and […]

0Comments